Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 12 May 2020

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study. 

Poor social support lowers rate of chemotherapy toxicity detection in elderly cancer patients

14 Mar 2020
There is a growing body of evidence that highlights numerous potential benefits of home chemotherapy to cancer patients.

Older cancer patients with poor social support (SS) were less likely to have documented grade 3–5 nonhaematological chemotherapy-related toxicities, a recent study has found.

Researchers enrolled 498 patients (mean age, 73±6.2 years) with solid cancers, in whom SS was assessed using a modified version of the Medical-Outcome Study-Social Support Survey. Toxicities were graded according to the Cancer Institute Common Toxicity Criteria for Adverse Events version 3.0.

More than half of the participants had at least one documented toxicity of grade 3–5. The median SS score was 95; most patients (74 percent) reported good SS, with scores above 75. Those with poor support tended to be older and were less likely to live with a partner or with a child.

The researchers found no clear linear relationship between SS and chemotherapy-related toxicities. The prevalence rates of grade 3–5 toxicities were 48.5 percent and 54.6 percent in those with poor vs good SS. Specifically, haematological toxicities were more common in participants with poor support (11.5 percent vs 9.2 percent), while the opposite was true for nonhaematological toxicities (22.3 percent vs 28.5 percent). None of the differences were statistically significant.

However, multivariate polychotomous logistic regression analysis found that those with poor SS were significantly less likely to have grade 3–5 toxicities (adjusted odds ratio [OR], 0.58; p=0.02), an effect driven by discrepancies in rates of grade 3–5 nonhaematological toxicities (adjusted OR, 0.52; p=0.02).

Notably, disaggregation according to individual SS survey items showed that the lower rates were likely driven by a lack of reporting. Grade 3–5 toxicity rates were significantly lower in participants who did not have someone to take them to the doctor “most” or “all of the time” (adjusted OR, 0.32; p=0.02).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 12 May 2020

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.